Member Info for inanaco

https://www.cbsnews.com/news/immunotherapy-treatment-saves-life-of-woman-with-late-stage-breast-cancer/

"" superior recursive killing potential by CD4+ CAR T cells """ Cd8's get exhausted ... The CD4's just keep killing ..

Scancell has already invaded the Car T space with the advanced TCR Format in its collaboration with BioNtech. Lindy has already shown Memory effect, which again is also highlighted in this paper that CD4 adaptive response is far superior to a CD8 response, hence "never seen anything like it in 30 years" Lindy Durrant. I keep highlighting Interferon Gamma is the way to increase inflamamtion and attract the attention of the immune system """" CD4+ CAR T cells secreted more IFN-γ """ so if you see IFN-y .... that's interferon gamma """ When administered to tumor-bearing mice, CD4+ T cells with tumor-specific TCRs were found to both mediate direct cytotoxicity against tumor cells and to provide helper function to evoke intrinsic antitumor immune responses (28, 31). Furthermore, in melanoma patients receiving immunocheckpoint blockade, a neoantigen-specific Th1 population was identified to account for the antitumor effect """" so yet again Scancell science is shown to work .... Now they have added that important subset ........ TH1 which are the CD4's that inflame and secrete IFN-y .... This is how Scancells science is de-risked, paper after paper of research done by others shows evidence that Scancells Papers are correct. which makes my life so easy ... Its not gambling.

Scancell tracks Englands Cricket team ...A good day .

yes i read that on the sc104, which is why i was very interested to track it down, and my thoughts concur ... just trying to piece the research together to form a picture, and to find out if any party had took the original further. Interesting to see just how long it takes to fully grasp process and the money involved and problems surfaced that can still be resolved by refining, these mabs are very powerful and exquisitely sensitive even a tiny error can cause serious issues, intrigued that Lindy never gave up even after they had been sold. Of course we still don't have conclusive evidence from scancell but i don't think we are far off the mark. With JC and CH with that Arana pedigree this is another indication just how close the current BOD are ...

could it be tracked by the patents ?

Bit of Digging hint (wildforce) what happened to the direct killing antibodies sold by scancell back in 2006 ? to Arana once Cephalon which took control of for $203 million http://www.pcrf.org.uk/pages/professor-lindy-durrant-2010-award.html trying to dig deeper into the recent RNS to see if we can find those antibodies, because we may have done a deal on this particular technology of which scancell has a clear advantage of understanding going back at least 15 years From recent RNS "also acquired a proprietary technology to enable the modification of the constant region (FC) of a human antibody to allow direct tumour killing" so the trail leads to Teva .http://www.tevapharm.com/news/teva_completes_acquisition_of_cephalon_10_11.aspx

the discussion was turned directly to scancell, so hardly Off topic, the BB has so few posts of interest boom that its not clogging up ... and to be honest its an endless digital paper

always will be .... laws are involved problem arises when you ask the people, they give an answer and you ignore it ... EU

I did say earlier that the Dr - Scancell relationship ... ie the marketing side of scancell which does not exist ... would be highly complex with both parties agreeing treatment ... so effectively Scancell would have to manufacture and market .... an unapproved product ..so this would have to be planned, and on what scale ... ? takes a year to get a batch manufactured ........ so you would have to Gear Up for this commercial area to work

but that's off label prescribing so Merck is not directly involved this is very different as Scancell would have to be involved

Its end stage treatment Crumbs, if it don't work its market share ends. and its not the patient that decides at the end of the day .. only the doctors signature is the deciding vote and that would not be a GP but a hospital consultant ...

that then could get very interesting crumbs ... levi 401 ......... released to the market LOL

ONW if you post with reasoning i will always engage with a sensible discussion

crumbs our posts crossed both carry a similar message ...

Doctors can already supply Off label ... ONW so in effect they are taking the responsibility not the supplier it really is just an opening up of this area It can work in the US ... as its a mainly private system .. here its way more difficult as its taxpayers money involved.

ONW you can consider this thou, i suspect that drugs to treat end stage cancer to be effective on a case by case basis would still have been and are still in trial, otherwise the data would not be available at all for any doctor to consider a prescription. So in Moditope case lets say it turns out to be safe, and very effective, at phase 2 results you could consider this option to treat on a non approved basis end stage cancer patients, however as we know, they will still need a minimum of 3 to 5 months of life available for the vaccine to get a foothold to break tolerance and possibly longer in patients that are immune compromised SCIB1 would not fall into this area, until its completed a phase 2 combo, as an adjuvant trials are to early stage to meet the Trump criteria. However the science is available to show it could be of benefit .... as a combo. But Who Pays ... ? Scancell cannot subsidise the system .. and scancell would have to "gear up" to manufacture and supply ....thus entering into a highly complex Dr To Manufacture relationship and the moral dilemma of treatment to patients with money but maybe cannot be saved. for the press then to come out with "greedy" ...

Unless something else turns up that has more efficacy we can only use the current standard of care for patients using a PD1 treatment regime or we have to run a combination trial in conjunction with a third party like Roche etc using an unapproved PD1 mono therapy in that indication Metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving TECENTRIQ. v KEYTRUDA is a prescription medicine used to treat a kind of lung cancer called non�small cell lung cancer (NSCLC). KEYTRUDA may be used alone as your first treatment when your lung cancer has spread (advanced NSCLC) and tests positive for �PD‑L1� and your tumor does not have an abnormal �EGFR� or �ALK� gene.

I have no idea what your posting ONW, i don't think you do ... all i see is repetitive negatives without substance

thought we had already discovered that ONW ... brakes off using PD1, accelerator pressed with immunobody or have you something else to consider ? that fits the Holy Grail .. ? You seem to think that immunobody induces only a singular adaptive response its actually a combo ... Tyrosinase-Related Protein 2 (TRP2) and gp100 plus two helper T cell epitopes.